Renovia, a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that researchers presented new data supporting the value of the leva® Pelvic Health System in treating female urinary incontinence (UI). Three accepted abstracts showed that leva delivers durable UI symptom improvement for 12 months following eight weeks of therapy, generates valuable real-world data that both supports leva’s effectiveness and provides an opportunity to…
